Alicia K. Morgans, MD

home / authors / alicia-k-morgans-md

Articles

Alicia K. Morgans, MD, MPH, from Dana-Farber Cancer Institute indicates that patients with non-metastatic castration-resistant prostate cancer are able to stay on treatment for long periods of time with darolutamide vs enzalutamide and apalutamide.

DEAR Study Offers ‘Hope’ to Patients With Non-Metastatic CRPC

June 23rd 2023

Alicia K. Morgans, MD, MPH, from Dana-Farber Cancer Institute indicates that patients with non-metastatic castration-resistant prostate cancer are able to stay on treatment for long periods of time with darolutamide vs enzalutamide and apalutamide.

Alicia Morgans, MD, MPH, on the Rationale for Examining the Clinical and Cost Impact of Cabazitaxel in mCRPC

Alicia K. Morgans, MD

October 11th 2021

CancerNetwork® sat down with Alicia Morgans MD, MPH, at the 2021 European Society for Medical Oncology Congress to talk about the rationale for analyzing the financial impact of cabazitaxel vs a second androgen receptor targeted agent in metastatic castration-resistant prostate cancer.

Addressing Physical, Cognitive Effects of ADT in Prostate Cancer Patients

Alicia K. Morgans, MD

May 31st 2017

In this interview ahead of ASCO 2017 we discuss the physical and cognitive effects of androgen deprivation therapy in older men treated for prostate cancer.